Hodgkin Lymphoma in Remission
Conditions
Keywords
epigenetic markers
Brief summary
Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics: * in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).
Detailed description
The study aims to evaluate patients with hodgkin lymphoma in complete remission for at least 2 years and newly diagnosed (stage II b, stage III or stage IV) as they are currently characterised by a long life expectancy during which there is an increased and early incidence of non-neoplastic systemic complications as well as, of course, manifestations of secondary malignancies.
Interventions
It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics: * in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification). * newly diagnosed (stage II b, III or IV, Ann Arbor Classification).
Sponsors
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma * Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy * Patients of both sexes aged ≥ 18 years at enrollment * Signature of informed consent
Exclusion criteria
* Concomitant second neoplasm
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA) | through study completion, an average of 2 year | Determine the biological age of patients |
| DNA methylation (methylation rate) | through study completion, an average of 2 year | Determine the biological age of patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA) | through study completion, an average of 2 year | Determine the possible acceleration of the biological age of patients |
| DNA methylation (methylation rate) | through study completion, an average of 2 year | Determine the possible acceleration of the biological age of patients |
Countries
Italy
Contacts
Primary ContactPier Luigi Zinzani, MD
Backup ContactCinzia Pellegrini, MD
Outcome results
None listed